Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast

About this update from Nutriband Inc.

[{"type":"image","alt":"Nutriband Inc.","displaySize":"","headline":null,"caption":"Nutriband Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/e1fe1a06910d514b950ca827bdf3c344"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6tS21qJunuW4HNsmR2WoLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNQ--/https://media.zenfs.com/en/globenewswire.com/e1fe1a06910d514b950ca827bdf3c344","width":300,"height":82}},"lazy":false},{"type":"text","content":"ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jack Neel Podcast to discuss the opioid crisis, the Company’s AVERSA technology and the opportunity for Nutriband to improve the safety profile of easily abused medications.","length":370,"tagName":"p"},{"type":"text","content":"Interested shareholders may find the link to the latest youtube episode here https://youtu.be/HB6E7TxGXqg?si=VU6c57saNbdzxraH.","length":126,"tagName":"p"},{"type":"text","content":"The Episode can also be found on Spotify, iTunes, Amazon music and www.jackneel.com","length":88,"tagName":"p"},{"type":"text","content":"About AVERSA™ Abuse-Deterrent Transdermal Technology","length":52,"tagName":"p"},{"type":"text","content":"Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.","length":633,"tagName":"p"},{"type":"text","content":"About Nutriband Inc.","length":20,"tagName":"p"},{"type":"text","content":"We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ techn...

More updates from Nutriband Inc.